Alba 
Sitemapcontactlogin 

2014

February 11, 2014 - Baltimore, MD, February 11, 2014 - -Alba Therapeutics Corporation announced today the positive results of their Phase IIb trial evaluating its investigational product, larazotide acetate, a first-in-class tight junction regulator, intended for the treatment of patients with celiac disease (CeD).

2013

November 5, 2013 - Baltimore, MD, November 5, 2013 - - Alba Therapeutics Corporation today announced the appointment of Wendy Perrow as its Chief Executive Officer (CEO).  Her responsibilities include managing the Company's business, clinical, financial, licensing, and corporate development efforts.  Ms. Perrow previously served as President and COO and she has been a member of Alba's executive management team since 2008.

2012

May 1, 2012 May 1, 2012 - Baltimore, MD, May 1, 2012 - - Alba Therapeutics Corporation today announced that it was granted a certificate of registration for copyright of the first and only Patient Reported Outcome (PRO) questionnaire for patients with Celiac Disease (CeD). The CeD PRO questionnaire will be used as part of Alba’s clinical trial program evaluating its investigational compound larazotide acetate, in patients with celiac disease. Alba’s Phase 2b clinical study (CLIN1001-012) is currently accepting patients in the U.S. and Canada.2009

March 17, 2009 - Alba Therapeutics Corporation announced today it will initiate further clinical studies for patients diagnosed with celiac disease with their lead compound, larazotide acetate.

2008

November 11, 2008 - Alba Therapeutics Announces Enrollment of Its First European Patient in Global Phase IIb Study of Larazotide Acetate for Treatment of Active Celiac Disease

October 7, 2008 - Alba Therapeutics Presents New Data for Larazotide Acetate at the 2008 American College of Gastroenterology Annual Scientific Meeting

October 2, 2008 - Alba Therapeutics Announces Promotions

May 20, 2008 - Alba Therapeutics Announces the Presentation of Results of a Phase IIa Clinical Trial for Larazotide Acetate for the Treatment of Celiac Disease at the Digestive Disease Week Conference

May 16, 2008 - Alba Therapeutics Announces the Enrollment and Randomization of the First Patient in the Phase IIb Clinical Trial for Larazotide Acetate (AT-1001) for the Treatment of Active Celiac Disease

April 3, 2008 - Alba Therapeutics Announces Appointment of Bruce A. Peacock as its Chief Executive Officer

March 18, 2008 - Blake M. Paterson MD, CEO and Co-founder of Alba Therapeutics, Wins Greater Baltimore Committee 2008 Leadership in Bioscience Award

January 18, 2008 - Alba Therapeutics Appoints Wendy Perrow as its Vice President, Marketing and Alliance Management